Trademark applications and grants for Tasly Pharmaceutical Group Co L T D. Tasly Pharmaceutical Group Co L T D has 2 trademark applications. The latest application filed is for "TASLY"
Patent Application | Date |
---|---|
PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VE 20220151984 - 17/588033 SUN; He ;   et al. | 2022-05-19 |
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PREVENTING AND/OR TREATING ISCHEMIC REPERFUSION INJURY 20210038668 - 17/041795 HAN; Jingyan ;   et al. | 2021-02-11 |
PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 20210000853 - 16/976832 ZHOU; Shiuiping ;   et al. | 2021-01-07 |
FORMULATION OF A MICRO DROP PILL AND THE PREPARATION METHOD THEREOF 20190274962 - 16/422857 Yan; Xijun ;   et al. | 2019-09-12 |
APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION 20190046500 - 16/073507 HAN; Min ;   et al. | 2019-02-14 |
Mark Image Registration | Serial | Trademark Application Date |
---|---|
![]() "TASLY" 5477867 79214474 |
TASLY 2016-11-10 |
![]() "TASLY" 3128633 78277157 |
TASLY 2003-07-22 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.